New Data on CYP2C19 Loss-of-Function Alleles Questions Impact of Plavix PGx Testing
September 01, 2010
New Data on CYP2C19 Loss-of-Function Alleles Questions Impact of Plavix PGx Testing
Findings in a NEJM study this week challenged previously reported data that alleles in the CYP2C19 gene can limit how certain carriers of the polymorphisms respond to Plavix.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UF to Genotype All Comers at Cath Lab to Personalize Treatment with Plavix, Eventually Other Drugs
June 27, 2012 / Pharmacogenomics Reporter - Study Finds Genomic/Clinical Combo to Be Best Predictor of Complications in Stent Patients on Plavix
November 2, 2011 / Pharmacogenomics Reporter - Medco to Compare Effient vs. PGx-Guided Plavix in Heart Patients on Prevacid
July 28, 2010 / Pharmacogenomics Reporter - Medco Study to Gauge Whether PGx-Based Plavix Dosing is as Effective as Higher-Priced Effient
October 21, 2009 / Pharmacogenomics Reporter - GWAS Links CYP2C19 to Plavix Response; Randomized-Controlled Trial, PGx Consortium to Come
August 26, 2009 / Pharmacogenomics Reporter